> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Tectonic Therapeutic Expects Heart-Failure Trial Results By End Of January, With $234.7 Million In Cash
- URL: https://www.bullished.co/tectonic-therapeutic-expects-heart-failure-trial-results-by-end-of-january-with-234-7-e307f339/
- Published: 2026-11-06T12:42:35.000Z
- Updated: 2026-11-06T12:42:35.000Z
- Description: The biotech reported a $21.3 million third-quarter net loss and says its cash should last into the first quarter of 2029.
- Author: Matteo Parrino
- Tags: Earnings, TECX, Industry: Healthcare

Tectonic Therapeutic, a clinical-stage biotech developing antibodies and proteins aimed at cell-surface receptors, said topline results from its Phase 2 APEX trial of TX45 in pulmonary hypertension tied to heart failure are [anticipated by the end of January 2027](https://www.sec.gov/Archives/edgar/data/0001681087/000119312526449965/tecx-ex99%5F1.htm?ref=bullished.co). The company disclosed the timing Thursday with third-quarter results, along with [$234.7 million in cash](https://www.sec.gov/Archives/edgar/data/0001681087/000119312526449965/tecx-ex99%5F1.htm?ref=bullished.co) that it expects to last into the first quarter of 2029.

## APEX readout is the nearest catalyst

APEX is a global, randomized, placebo-controlled, 24-week trial of subcutaneous TX45 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. Its main goal is the change in pulmonary vascular resistance from baseline in a subgroup with combined pre- and post-capillary disease.

Enrollment finished in June 2026\. In July, an independent data monitoring committee recommended the trial continue without modification, as the company had previously disclosed.

CEO Alise Reicin, M.D., called the readout "a critical milestone for TX45." Tectonic's press release says no medications have been approved for this form of pulmonary hypertension.

TX45 is also in ALPINE, an open-label Phase 2a trial in up to 25 patients with pulmonary hypertension tied to interstitial lung disease. The first patient was dosed in October, and interim topline results are expected in the second half of 2027.

## A second drug moves toward patients

The company's other candidate, TX2100, targets hereditary hemorrhagic telangiectasia, a rare inherited bleeding disorder. The FDA granted it Fast Track designation in September 2026 and cleared the application for a Phase 1b trial in August 2026.

In healthy volunteers, TX2100 showed no serious adverse events at any dose across six single-dose cohorts, and no anti-drug antibodies were detected. The Phase 1b TERRA trial, planned for about 20 patients, is expected to start by year-end 2026, with interim results by year-end 2027\. A placebo-controlled Phase 2 trial is expected to begin in early 2027.

## Loss widens, cash runway holds

The net loss for the three months ended September 30 was $21.3 million, against $19.0 million a year earlier, or $1.08 a share. Research and development spending was $17.4 million, up from $16.9 million, and general and administrative costs were $6.0 million, up from $5.0 million. The company attributed both increases mainly to higher employee costs, including non-cash stock-based pay.

Cash stood at [$234.7 million](https://www.globenewswire.com/news-release/2026/11/05/3396988/0/en/tectonic-therapeutic-announces-third-quarter-2026-financial-results-and-recent-business-highlights.html?ref=bullished.co) at September 30, up from $227.1 million at June 30 and down from $253.8 million at December 31, 2025\. The balance includes about $22.3 million in net proceeds from an at-the-market stock offering during the quarter.

Tectonic says that cash should last into the first quarter of 2029, through the TX45 Phase 2 readouts in both indications.

APEX topline results are due by the end of January 2027, and the TERRA trial is expected to start by year-end 2026.

Learn

- [Item 2.01: completion of an acquisition or disposition →](https://www.bullished.co/learn/8-k-items-explained/#item-201-completion-of-an-acquisition-or-disposition)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Tectonic Therapeutic, Inc. (TECX)](https://www.sec.gov/Archives/edgar/data/0001681087/000119312526449965/tecx-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tecx-ex99\_1.htm — Tectonic Therapeutic, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001681087/000119312526449965/tecx-ex99%5F1.htm?ref=bullished.co) — SEC EDGAR
- [Tectonic Therapeutic Announces Third Quarter 2026 Financial](https://www.globenewswire.com/news-release/2026/11/05/3396988/0/en/tectonic-therapeutic-announces-third-quarter-2026-financial-results-and-recent-business-highlights.html?ref=bullished.co) — globenewswire.com